EQS-Adhoc: BRAIN Biotech AG signs new Revolving Credit Facility with MP Beteiligungs-GmbH

NOT FOR DISTRIBUTION OR DISSEMINATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR DISSEMINATION WOULD BE UNLAWFUL. OTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

BRAIN Biotech AG signs new Revolving Credit Facility with MP Beteiligungs-GmbH

Zwingenberg, Germany, July 13, 2026 – BRAIN Biotech AG (ISIN DE0005203947; “BRAIN” or “Company”) has entered into an agreement with MP Beteiligungs-GmbH (MPBG) for a new revolving credit line of €9.0 million. The term ends on December 31, 2028. Interest on the loan amount drawn will be charged at a variable market-conform interest rate of 6-Month-Forward-Euribor plus 233 basis points per annum. This revolving credit line is intended for general corporate financing purposes and scheduled debt services.

Notifying person:

Martina Schuster

BRAIN Biotech AG

– Investor Relations –

Darmstädter Str. 34-36

64673 Zwingenberg

Deutschland
 

www.brain-biotech.com

Investor Relations Office

Tel.: +49-(0)-6251-9331-0

Fax: +49-(0)-6251-9331-11

E-Mail: ir@brain-biotech.com

IMPORTANT NOTICE

This announcement may not be published, distributed or released in the United States of America (including its territories and possessions, any state of the United States of America and the District of Columbia), Australia, Canada, Japan or any other jurisdiction in which the publication, distribution or release would be unlawful. This announcement does not constitute an offer of securities of the company for sale or a solicitation of an offer to purchase securities of the company. There will be no public offer of securities of the Company.